Salminen, Jukka K. http://orcid.org/0000-0002-6164-2395
Mehtola, Aino
Talala, Kirsi
Taari, Kimmo
Mäkinen, Jussi
Peltola, Jukka
Tammela, Teuvo L. J.
Auvinen, Anssi
Murtola, Teemu J.
Article History
Received: 27 February 2021
Revised: 4 March 2022
Accepted: 31 March 2022
First Online: 3 May 2022
Competing interests
: TLJT has served as a paid consultant for Amgen, Astellas, Bayer, Ferring and Roche. TJM has served as a paid consultant for Astellas, GSK and Janssen Cilag. KT has received support from research funding from Medivation/Astellas/Pfizer, Orion and Myovant. JP has participated in clinical trials for Eisai, UCB and Bial; received research grants from Eisai, Medtronic, UCB and LivaNova; received speaker honoraria from LivaNova, Eisai, Medtronic, Orion Pharma and UCB; received support for travel to congresses from LivaNova, Eisai, Medtronic and UCB and participated in advisory boards for Arvelle, Novartis, LivaNova, Eisai, Medtronic, UCB and Pfizer. The remaining authors declare no competing interests.
: Study protocol was approved by ethics committee of Pirkanmaa Hospital District. Study is epidemiologic retrospective study so need for consent was waived. Study was performed in accordance with the Declaration of Helsinki.
: Article does not contain any individual person‘s data.